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Available online 4 August 2016Chronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;22) translocation,
generating Ph1 chromosome and BCR-ABL oncogene in a primitive hematopoietic stem cell (HSC). The resistance
of HSC to targeted therapies using tyrosine kinase inhibitors remains amajor obstacle towards the cure.We have
generated an iPSC line from a patient with CML using leukemic CD34+ cells cryopreserved at diagnosis. Ph1+
CML cells were reprogrammed by non-integrative viral transduction. These iPSCs harboured Ph1 chromosome
and expressed pluripotency hallmarks as well as BCR-ABL. Teratoma assays revealed normal differentiation
after injection in immunodeﬁcient mice.
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Chronic myeloid leukemia (CML) is a malignant myeloproliferative
disorder originating from a primitive hematopoietic stem cell leading
to an expansion of the progenitors and differentiated myeloid cells in
the peripheral blood (Chomel and Turhan, 2011). Despite the major
progress obtained in this disease by the use of tyrosine kinase inhibitors,
themost primitive stemcells are resistant to these therapies (Jiang et al.,
2007; Chomel et al., 2011). We have generated iPSC from the cryopre-
served diagnostic sample of a patient according to his clinical response
to Imatinib, the ﬁrst clinically licensed tyrosine kinase inhibitor. This
14-year old young patient exhibited a clear resistance to this drug
with absence ofmolecular response after 18months of starting therapy.
There was no mutation in the ABL-kinase domain of the BCR-ABL gene.
In 2005, given his young age and the availability of a HLA-compatible
sibling, an allogeneic stem cell transplant was performed with success.
In 2016, he remains in good health in complete haematological andmo-
lecular remission. An induced pluripotent stem cell (iPSC) line were
generated using cryopreserved CD34+ leukemic cells collected at diag-
nosis by non-integrative transduction of Oct3/4, Sox2, Klf4, and cMyc
(Takahashi et al., 2007). iPSC colonies growing on MEF stromal layers
were morphologically identiﬁed after 2–4 weeks (Fig. 1A), individually
plucked as well as a polyclonal stock and expanded. Besides the
polyclonal PB32 cell line, 3 clones (PB32–1, PB32–4 and PB32–5) were
expanded. All have been characterized for their pluripotency. They ex-
hibited typical markers of pluripotency such as expression of SSEA4the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ii
m
n
n
g
ca
A. B. C.
D.
Fig. 1. Characterization of the PB32 Ph1-positive iPSC cell line. Panel A: Phase contrast imaging of PB32 colonies (polyclonal stock) grown onMEF stromal cells. Panel B: FACS evaluation of
pluripotencymarkers using a double SSEA4 and TRA-1-60 staining conﬁrming the presence of cell surface pluripotencymarkers on PB32 cells. Panel C: Cytogenetics analysis showing the
presence of Ph1 chromosome (arrow). PanelD: Pathological analysis of a teratoma fromPB32 iPSC, showing a normal ectodermal, endodermal andmesodermal differentiation.M:Muscle;
i: Intestinal tissue with mucus formation; g: Glial tissue; n: Neural crest; ca: Cartilage.
236 G. Telliam et al. / Stem Cell Research 17 (2016) 235–237and TRA-1-60 (Fig. 1B). Cytogenetics analysis demonstrated the
presence of Ph1 chromosome (Fig. 1C). Teratoma assays showed the
presence of normal differentiation towards endodermal, ectodermal
and mesodermal layers (Fig. 1D).
Materials and methods
Generation of CML iPSC
Cryopreserved leukemic CD34+ peripheral blood mononuclear
cells (PBMC) obtained at diagnosis were thawed and expanded in
Myelocult™ medium (Stemcell Technologies) supplemented with 1%
penicillin-streptomycin (Life technologies), hSCF (100 ng/ml), hFLT-3
(100 ng/ml), hIL-3 (20 ng/ml), hIL-6 (20 ng/ml) and hIL7 (20 ng/ml)
(all of them from Peprotech) for 4 days. At day + 4, 2 × 105 CD34+
cells were then transduced overnight with Sendai viruses containing
Oct3/4, Sox2, Klf4, and c-Myc (CytoTune®-iPS Sendai Reprogramming
Kit, Life technologies), each of them at multiplicity of infection (MOI)
of 15. Following the next 2 days, cell culture medium was changed
daily and cells were resuspended in expansion medium after 5 minute
centrifugation at 200 ×g. At day + 3, cells were recovered by centrifu-
gation andplated onMitomycin-C-treatedmouse embryonicﬁbroblasts
(MEF, CD1 strain) in expansion medium for 2 additional days. At day 6,
half of the medium was changed to human pluripotent stem cell medi-
um (hPSC medium) based on DMEM/F12 supplemented with 20%
Knock Out Serum Replacer, 1mM L-glutamine, 1% penicillin/streptomy-
cin, 100 μM2-mercaptoethanol (all of them from Life technologies) and
12.5 ng/ml basic FGF (Miltenyi Biotech). Then, the medium was
changed daily with hPSC medium. 3–4 weeks after the lentiviral trans-
duction,morphologically recognizable iPSC colonies appeared in culture
for both cell lines. These colonies weremanually picked and transferred
to freshly Mitomycin-C-treated MEF for ampliﬁcation.
After generation of a frozen stocks, iPSC could be cultured using
either MEF co-culture technique or in feeder free conditions. The feeder
cultures were performed on Mitomycin C-treated MEF layer asdescribed abovewith passaging every 7 days using 1mg/ml collagenase
IV in DMEM/F12 (Life technologies); the feeder-free culture was
performed on Geltrex™ (Life technologies) in Essential 8 medium
(Life technologies) and 1% penicillin/streptomycin with passaging
every 3–4 days using in DPBS (Life technologies) supplemented with
0.5 mM EDTA (Life technologies) and 1.8 mg/l NaCl (Sigma).
Karyotyping and expression of BCR-ABL
For conventional cytogenetics, cells grown in 60 mm plates
(Corning) on mitomycin-C treated MEF for 5 days were cultured 2 h
in hPSC medium supplemented with 100 ng/ml Colcemid™ (Life tech-
nologies). Cells were detached from the plate by 5 min treatment with
1 ml per plate of TrypLE™ Express (Life technologies) at 37 °C, 5% CO2.
After triturationwith a P1000micropipet, 9ml of 0.075MKCl (Life tech-
nologies) were added to the cell suspension followed by incubation at
37 °C during 20 min to obtain an osmotic shock. Cell suspension was
then preﬁxed by the addition of 1 ml of ﬁxative composed of Metha-
nol/Acetic Acid (3:1) followed by 10 minute centrifugation at 130 ×g.
Cell pellet was then resuspended in 10 ml of ﬁxative and centrifuged
10 min at 130 ×g twice before a ﬁnal resuspension in 10 ml of ﬁxative.
Cells were then spread on slides and stained with Giemsa. A minimum
of 10 metaphases were captured and analysed using an automated im-
aging system (Meta Systems).
Pluripotency markers and BCR-ABL expression
For ﬂow cytometry analysis, iPSC polyclonal stock and three clones
PB32-1, PB32-4 and PB32-5 were recovered from Mitomycin-C
inactivated MEF after incubation for 2 h in 1 mg/ml collagenase IV in
DMEM/F12. After two cycles of washing/sedimentation with 10 ml
DMEM/F12, colonies were washed once in Ca2+/Mg2+ free PBS (Life
technologies) and then dissociated into a single cell suspension by
10 min incubation in Hank's balanced enzyme-free cell dissociation
buffer (Life Technologies). For pluripotency marker analysis, 1 × 105
237G. Telliam et al. / Stem Cell Research 17 (2016) 235–237cells were incubated in 10 μl PBS containing 1 μl V450-conjugated
mouse monoclonal anti-SSEA-4 and 1 μl Alexa647-conjugated mouse
monoclonal antibody anti-TRA1-60 (both from BD Biosciences) or con-
jugated isotype control. BCR-ABL expression was performed by both Q-
RT-PCR and Western blots showing expression of BCR-ABL mRNA and
protein in PB32 polyclonal iPSC and three clones (data not shown).
In vivo pluripotency analysis by teratoma formation
Teratoma assays were performed triplicate in order to analyze the
development of potentially malignant tumor tissue within teratomas,
by intramuscular injection of PB32 polyclonal iPSC and three clones in
NSG mice (2.106 cells in 150 μl of Geltrex/DMEMEF12 1:1dilution).
10 weeks after injection, pathological analysis of teratomas was per-
formed. This analysis revealed the presence of differentiated tissues in-
cluding glial cells, neuroectodermal cells, intestinal cells and cartilage
differentiation in all tumorswith no evidence ofmalignancy, conﬁrming
the pluripotency of these cells (Fig. 1D).Acknowledgements
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